We are live on ! Find out more
IBT

International Biotechnology Trust Portfolio holdings

AUM $297M
1-Year Est. Return 17.25%
This Fund
S&P 500
This Quarter Est. Return
+4.48%
1 Year Est. Return
+17.25%
3 Year Est. Return
+11.14%
5 Year Est. Return
+79.35%
10 Year Est. Return
–
AUM
$329M
AUM Growth
-$29.9M
Cap. Flow
-$29.1M
Cap. Flow %
-8.87%
Top 10 Hldgs %
51.54%
Holding
77
New
13
Increased
17
Reduced
12
Closed
16

Top Buys

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$12.2M
2
APLS
Apellis Pharmaceuticals
APLS
+$8.46M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$7.07M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$6.94M
5
GILD icon
Gilead Sciences
GILD
+$6.94M

Top Sells

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$40.5M
2
ALKS icon
Alkermes
ALKS
+$16.7M
3
EXEL icon
Exelixis
EXEL
+$10.5M
4
QURE icon
uniQure
QURE
+$8.77M
5
RARE icon
Ultragenyx Pharmaceutical
RARE
+$8.53M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KDNY
76
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
– –
-319,989
Closed -$7.41M
1 2 3
4

Similar funds

DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
DT
Daniels + Tansey Wilmington, Delaware $289M AUM 18.06% 1-Year Est. Return
3LCM
3D/L Capital Management Hartford, Connecticut $308M AUM 13.67% 1-Year Est. Return
TFA
Triad Financial Advisors Greensboro, North Carolina $284M AUM 14.95% 1-Year Est. Return
SFG
Steward Financial Group Colleyville, Texas $315M AUM 13.78% 1-Year Est. Return
AEPLI
AH Equity Partners LSV I Menlo Park, California $315M AUM 9.31% 1-Year Est. Return
CC
Chanos & Company New York $318M AUM 4.62% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

International Biotechnology Trust's Q2 2023 Portfolio in Review

As of Q2 2023, International Biotechnology Trust held 77 positions worth $329M, down 8.3% from $358M the previous quarter. Its ten largest holdings account for 52% of the portfolio.

International Biotechnology Trust withdrew a net $29.1M in Q2 2023, closing 16 positions and reducing 12 holdings. Its most notable exit was Seagen Inc. Common Stock, an estimated $40.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

Against the trend, International Biotechnology Trust opened a new position in Horizon Therapeutics Public Limited Company Ordinary Shares worth $6.89M.

  • International Biotechnology Trust's largest Q2 2023 buy was Horizon Therapeutics Public Limited Company Ordinary Shares: 67,000 shares worth $6.89M.
  • International Biotechnology Trust added most to Regeneron Pharmaceuticals in Q2 2023, an estimated $12.2M increase.
  • International Biotechnology Trust's biggest Q2 2023 reduction was uniQure, cutting an estimated $8.77M.
  • International Biotechnology Trust fully exited Seagen Inc. Common Stock in Q2 2023, selling an estimated $40.5M.
  • International Biotechnology Trust's ten largest holdings make up 52% of its $329M portfolio in Q2 2023.
  • International Biotechnology Trust opened 13 new positions and closed 16 in Q2 2023.
  • International Biotechnology Trust's portfolio value fell 8.3% quarter-over-quarter to $329M.

Based on International Biotechnology Trust's 13F filing for Q2 2023, filed 8 Aug 2023.